Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-seminomatous germ cell tumors

International Journal of Urology

Volumn 11, Issue 9, 2004, Pages 763-767

  Muramaki, Mototsugu ^a   Hara, Isao ^a   Miyake, Hideaki ^b   Yamada, Yuji ^a   Okada, Hiroshi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

Chemotherapy; Non seminomatous germ cell tumor; Retroperitoneal lymph node dissection

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; TUMOR MARKER; VINBLASTINE;

ADULT; ARTICLE; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; HAZARD ASSESSMENT; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MALE; MULTIVARIATE ANALYSIS; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE; TERATOMA; TISSUE SECTION; TUMOR VOLUME;

ADULT; GERMINOMA; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECROSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TERATOMA; TESTICULAR NEOPLASMS;

EID: 6344237147     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00893.x     Document Type: Article

References (17)

1. Gerl A, Clemm C, Schmeller N et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br. J. Cancer 1994; 70: 960-5.
2. Einhorn LH. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol. 1990; 8: 1777-81.
3. Toner GC, Panicek DM, Heelan RT et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J. Clin. Oncol. 1990; 8: 1683-94.
4. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J. Clin. Oncol. 1992; 10: 569-73.
5. Steyerberg EW, Gerl A, Fossa SD et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J. Clin. Oncol. 1998; 16: 269-74.
6. Fox EP, Weathers TD, Williams SD et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol. 1993; 11: 1294-9.
7. Donohue JP, Rowland RG, Kopecky K et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J. Urol. 1987; 137: 1176-9.
8. American Joint Committee in Cancer. Testis. In: Greene FL, Page DL, Fleming ID et al. (eds). American Joint Committee in Cancer: AJCC Staging Manual, 5th edn. Lippincott-Raven Publishers, Philadelphia, 1997; 225-30.
9. Donohue JP, Rowland RG. The role of surgery in advanced testicular cancer. Cancer 1984; 54: 2716-21.
10. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981; 48: 904-908.
11. Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J. Clin. Oncol. 1997; 15: 1455-64.
12. Steyerberg EW, Vergouwe Y, Keizer HJ, Habbema JD. Residual mass histology in testicular cancer: development and validation of a clinical prediction rule. Stat. Med. 2001; 20: 3847-59.
13. Steyerberg EW, Keizer HJ, Habbema JD. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT study group. Int. J. Cancer 1999; 83: 856-9.
14. McGuire MS, Rabbani F, Mohseni H, Bains M, Motzer R, Sheinfeld J. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int. 2003; 91: 469-73.
15. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J. Clin. Oncol. 2003; 21: 3310-17.
16. Wahle GR, Foster RS, Bihrle R, Rowland RG, Bennett RM, Donohue JP. Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J. Urol. 1994; 152: 428-30.
17. Stenning SP, Parkinson MC, Fisher C et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998; 83: 1409-19.